Filing Flows

Filing Flows › C4 Therapeutics (CCCC) › Next earnings date

C4 Therapeutics (CCCC) earnings: beat the estimate

C4 Therapeutics (CCCC) reported on Nov 5, 2026 and beat the EPS estimate: −$0.16 against −$0.21 (+22.6%). Revenue was $8.5M for Q3 2026, -25% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+22.6% vs estimate
Beat rate100%

The last report

C4 Therapeutics reported revenue of $8.5M for the third quarter 2026 (-25% Y/Y), net loss $21.8M. How it makes money → · Every quarter →

C4 Therapeutics: EPS against the estimate, last 5 reportsC4 Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.39−$0.30Nov 25−$0.39−$0.18Feb 26−$0.26−$0.20May 26−$0.23−$0.18Aug 26−$0.21−$0.16Nov 26
Latest (Nov 26): Estimate −$0.21, Reported −$0.16.

C4 Therapeutics' latest quarter

C4 Therapeutics, Q3 2026: revenue $8.5M (-25% year over year), operating margin -290.5%, net loss $21.8M, operating cash flow −$26.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did C4 Therapeutics beat earnings?

C4 Therapeutics (CCCC) reported on Nov 5, 2026 and beat the EPS estimate: −$0.16 against −$0.21 (+22.6%).

When does CCCC report earnings?

The next date is not set yet.

Does C4 Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.